Obesity drug interaction study completed in healthy volunteers
NCT ID NCT07056842
First seen Apr 01, 2026 · Last updated May 24, 2026 · Updated 10 times
Summary
This study looked at how two common drugs, rifampin and itraconazole, change the way the body processes a new experimental medicine called VCT220, which is being developed for obesity. Thirty-two healthy adults took part, with each person receiving either rifampin or itraconazole alongside a single dose of VCT220. The goal was to measure drug levels in the blood and check for side effects, helping researchers understand safe dosing for future studies.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OBESITY & OVERWEIGHT are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
The First Affiliated Hospital of Shandong First Medical University
Jinan, Shandong, 250014, China
Conditions
Explore the condition pages connected to this study.